- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.
This educational activity is designed to provide our faculty with alternative sources of information and experience on controversial areas in diagnostic pathology that cannot be gleaned from reading the literature or standard textbooks in pathology. There are many areas in pathology where a uniformly acceptable standard has not yet been established. Direct interaction with an expert can provide the pathologist with additional insight into more effective ways to handle the issue.
At the conclusion of this activity, learners will be able to:
Describe CAR-T cell technology and its role in B-Cell Malignancies
Discuss clinical outcomes to date for CD19 CAR-T cell therapy in ALL and NHL
Identify future directions in CAR-T cell therapy
Nirav Shah, MD
Division of Hematology and Oncology
Froedtert and the Medical College of Wisconsin
All persons in control of content have NO relevant financial relationships to disclose except the following:
|Nirav Shah, MD, MS||Kite Pharma||Advisory Board|
|Nirav Shah, MD, MS||Juno Pharmaceuticals||Advisory Board|
|Nirav Shah, MD, MS||Miltenyi Biotec||Speaker/Research|
|Nirav Shah, MD, MS||Celegene||Consultant|
|Nirav Shah, MD, MS||Incyte||Consultant|